Novel Insights on CAI-CORM Hybrids: Evaluation of the CO Releasing Properties and Pain-Relieving Activity of Differently Substituted Coumarins for the Treatment of Rheumatoid Arthritis.

Abstract

Pain control is among the most important healthcare services in patients affected by rheumatoid arthritis (RA), but the current therapeutic options (i.e., disease-modifying anti-rheumatic drugs) are limited by the risk of the side effects. In this context, we proposed an innovative approach based on the hybridization between carbonic anhydrase inhibitors (CAIs) and CO releasing molecules (CORMs). The resulting CAI-CORM hybrids were revealed to possess strong anti-inflammatory effects in in vitro models of diseases and to relieve ache symptoms in an in vivo RA rat model. In this work, we have deepened the study of these promising hybrids, designing a library of coumarin-based compounds, also including internal dicobalt hexacarbonyl systems. The results obtained from the CO releasing study, the CA inhibitory activity, and the in vivo pain-relief efficacy evaluation in the RA rat model confirmed the success of this strategy, allowing us to consider CAI-CORM hybrids promising anti-nociceptive agents against arthritis.

• Authors: Emanuela Berrino, Laura Micheli, Simone Carradori, Lorenzo di Cesare Mannelli, Paolo Guglielmi, Alessandro De Luca, Fabrizio Carta, Carla Ghelardini, Daniela Secci, Claudiu T Supuran
• Journal: Journal of medicinal chemistry (J Med Chem) Vol. 66 Issue 3 Pg. 1892-1908 (02 09 2023) ISSN: 1520-4804 [Electronic] United States
• PMID: 36701258 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antirheumatic Agents
• Carbonic Anhydrase Inhibitors

Topics

• Rats
• Animals
• Arthritis, Rheumatoid (drug therapy)
• Pain (drug therapy)
• Antirheumatic Agents (therapeutic use)
• Carbonic Anhydrase Inhibitors (pharmacology)
• Pain Management